Business Wire

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

9.12.2022 00:05:00 EET | Business Wire | Press release

Share

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy.

Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tumor types. We wish to thank the patients, their families and healthcare teams for their participation in this clinical trial.”

The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified. Detailed findings from CONTACT-01 will be submitted for presentation at a future medical meeting.

ENDS

About CONTACT-01
CONTACT-01 is a global, multicenter, randomized, phase 3, open-label study that enrolled 366 patients who were randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab and the control arm of docetaxel. The study enrolled patients with both squamous and non-squamous NSCLC who progressed during or following anti-PD-1/PD-L1 therapy administered either concurrently or sequentially with chemotherapy. The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, objective response rate and duration of response. Results from cohort 7 of the phase 1b COSMIC-021 trial informed the CONTACT-01 trial design. CONTACT-01 was sponsored by Roche and co-funded by Exelixis. Both Ipsen and Takeda Pharmaceutical Company Limited (Takeda) opted in to participate in the trial and are contributing to the funding for this study under the terms of the companies’ respective collaboration agreements with Exelixis. More information about the trial is available at ClinicalTrials.gov.

About CABOMETYX® (cabozantinib)

Cabometyx is a multi-targeted tyrosine kinase inhibitor (TKI) with targets including vascular endothelial growth factor receptor (VEGFR), c-MET and the TAM receptor family, which block the growth of cancer.

Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of Cabometyx outside of the U.S. and Japan. Exelixis granted exclusive rights to Takeda for the commercialization and further clinical development of Cabometyx for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize Cabometyx in the U.S.

In over 60 countries outside of the United States and Japan, including in the European Union (E.U.), Cabometyx is currently indicated as:

  • Monotherapy for advanced renal cell carcinoma:
    • as first-line treatment of adult patients with intermediate or poor risk
    • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
  • In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults
  • Monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy
  • Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com

Ipsen’s Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2021 Universal Registration Document, available on ipsen.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors
Craig Marks
Vice President, Investor Relations
+44 7584 349 193

Media
Joanna Parish
Global Head of Franchise Communications Oncology
+44 7840 023 741

Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 6 64 26 17 49

Ioana Piscociu
Senior Manager
Global Media Relations
+33 6 69 09 12 96

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release

Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release

Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release

Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye